Effects of Aerobic and Resistance Training on Accumulation of Old, Modified Proteins in Young and Older Adults
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01477164|
Recruitment Status : Completed
First Posted : November 22, 2011
Last Update Posted : August 8, 2017
Muscle proteins accumulate damage during aging and leads to the loss of muscle mass and function in older people. Exercise can increase the making of new proteins and removal of older proteins, but it is not known if the effect changes with aging or type of exercise. The investigators will determine the ability for endurance, resistance, or a combination of exercise training to remove older-damaged proteins and make newer-functional muscle proteins in groups of younger and older people. The investigators will particularly study protein that are involved with energy production (mitochondrial proteins) and force production (contractile proteins).
Hypothesis 1: Older people will have greater accumulation of damaged proteins than younger people.
Hypothesis 2: Aerobic exercise will decrease the accumulation of damaged forms of contractile and mitochondrial proteins in younger and older people.
Hypothesis 3: Resistance exercise will decrease the accumulation of damaged forms of contractile proteins in younger and older people.
|Condition or disease||Intervention/treatment||Phase|
|Sarcopenia||Behavioral: High intensity aerobic exercise Behavioral: Resistance exercise training Behavioral: Combined||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||72 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Effects of Aerobic and Resistance Training on Accumulation of Old, Modified Proteins in Young and Older Adults|
|Study Start Date :||November 2011|
|Actual Primary Completion Date :||May 2016|
|Actual Study Completion Date :||March 2017|
Experimental: Aerobic Exercise Training
Participants will perform 12-weeks of high intensity aerobic training.
Behavioral: High intensity aerobic exercise
Participants will perform 12-weeks of high intensity aerobic training. Training will be 5-days per week. Three days (e.g. Monday, Wednesday and Friday) will include repeated bouts of cycling for 4-minutes at ~90% maximal effort followed by 3 minutes of active rest. The other two days (e.g. Tuesday and Thursday) will be treadmill exercise for 45 minutes at 70% of maximal effort.
Active Comparator: Combined
The combined group will have 12-weeks of no exercise followed by 12-weeks of combined aerobic and resistance exercise training. Assessments will be made at three time points: baseline, after 12-weeks of no training, and after 12-weeks of combined training.
The combined group will be assessed before and after 12 weeks of no exercise training, then again following 12 weeks of combined aerobic and resistance exercise training.
Experimental: Resistance Exercise Training
Participants will perform 12-weeks of resistance exercise training.
Behavioral: Resistance exercise training
Participants will perform 12-weeks of resistance exercise training. Training will be 5-days per week of daily sessions of 60 minutes that include resistance exercise for all major muscle groups.
- Skeletal muscle protein synthesis rate [ Time Frame: Approximately 14 weeks for the endurance or resistance training groups and approximately 28 weeks for the combined group ]The investigators will determine the rate of incorporation of stable isotope amino acid tracers in skeletal muscle proteins during several hours of rest. The measurement will be an average resting muscle protein synthesis rate (% new muscle protein per hour) and will be performed at baseline and following 12 weeks of exercise training.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01477164
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||K. Sreekumaran Nair, M.D., Ph.D.||Mayo Clinic|